Artificial Intelligence (AI) in Drug Discovery Market worth $4.0 billion by 2027 | NVIDIA Corporation (US), Microsoft Corporation (US), Google (US), Exscientia (UK), Schrödinger (US), Atomwise, Inc. (US), BenevolentAI (UK), NuMedii (US)

AI in Drug Discovery Market size is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period, according to the new recent study published by MarketsandMarkets™.

The growth of this Artificial Intelligence in Drug Discovery Market is driven by the growing need to control drug discovery & development costs, and growing number of cross-industry collaborations and partnerships, On the other hand, a lack of data sets in the field of drug discovery and the inadequate availability of skilled labor are some of the factors challenging the growth of the market.

Browse in-depth TOC on "Artificial Intelligence (AI) in Drug Discovery Market"
177 - Tables
33 - Figures
198 - Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=151193446&utm_source=OPenpr&utm_campaign=paid&utm_content=referral

North America is expected to dominate the Artificial Intelligence in Drug Discovery Market in 2022.

North America accounted for the largest share of the global AI in drug discovery market in 2021 and also expected to grow at the highest CAGR during the forecast period. North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. Presence of key established players, well-established pharmaceutical and biotechnology industry, and high focus on R&D & substantial investment are some of the key factors responsible for the large share and high growth rate of this market

Prominent players in Artificial Intelligence in Drug Discovery Market:

NVIDIA Corporation (US),
Microsoft Corporation (US),
Google (US),
Exscientia (UK),
Schrödinger (US),
Atomwise, Inc. (US),
BenevolentAI (UK),
NuMedii (US),
BERG LLC (US),
Cloud Pharmaceuticals (US),
Insilico Medicine (US),
Cyclica (Canada),
Deep Genomics (Canada),
IBM (US),
BIOAGE (US),
Valo Health (US),
Envisagenics (US),
twoXAR (US),
Owkin, Inc. (US),
XtalPi (US),
Verge Genomics (US),
Biovista (US),
Evaxion Biotech (Denmark),
Iktos (France),
Standigm (South Korea), and
BenchSci (Canada).

Players adopted organic as well as inorganic growth strategies such as product upgrades, collaborations, agreements, partnerships, and acquisitions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global AI in Drug Discovery Industry.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=151193446&utm_source=OPenpr&utm_campaign=paid&utm_content=referral

Ai In Drug Discovery Market Dynamics

What benefits AI show in drug discovery and development process?

Drug discovery is a very costly and lengthy process, owing to which there is a need for alternative tools for discovering new drugs. Drug discovery and development are commonly conducted through in vivo and in vitro methods, which are very costly and time-consuming. Furthermore, it takes ~10 years on average for a new drug to enter the market at a cost of ~USD 2.6 billion (Source: Biopharmaceutical Research and Development.org). Several players operating in this market are developing platforms that can help in the rapid discovery of drugs. For instance, Insilico Medicine (US) developed an AI-based drug discovery system, GENTRL, with which it could develop six experimental novel molecules within 21 days.

How and why AI workforce shortage is important retraining factor holding back the growth of the market?

AI is a complex system, and companies require a workforce with specific skill sets to design, manage, and implement AI systems. Personnel dealing with AI systems should be familiar and aware of technologies such as machine intelligence, deep learning, cognitive computing, image recognition and other AI technologies. Additionally, integrating AI technologies into existing systems is a challenging task that necessitates substantial data processing in order to replicate human brain behavior. Even slight errors might cause system failure and have a negative impact on the desired outcome. The absence of professional standards and certifications in AI/ML technologies is restraining the growth of AI

What are the emerging markets for Artificial Intelligence in Drug Discovery?

Emerging economies such as India, China, and countries in the Middle East are expected to offer potential growth opportunities for players operating in the AI in drug discovery market. In most of these countries, the demand for pharmaceuticals is expected to increase significantly, owing to the rising incidence of chronic and infectious diseases, increasing income levels, and improving healthcare infrastructure. As a result, these markets are very attractive for companies whose profit margins are affected by stagnation in mature markets, the patent expiration of drugs, and increasing regulatory hurdles.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=151193446&utm_source=OPenpr&utm_campaign=paid&utm_content=referral

Scope of the Artificial Intelligence (AI) in Drug Discovery Market Report:

Services segment is expected to grow at the highest rate during the forecast period.
Machine learning technology segment accounted for the largest share of the global Artificial Intelligence in Drug Discovery Market.
The immuno-oncology application segment accounted for the largest share of the Artificial Intelligence (AI) in Drug Discovery Market in 2021.
Pharmaceutical & biotechnology companies segment accounted for the largest share of the global AI in drug discovery industry.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/ai-in-drug-discovery-market.asp
Visit Our Web Site: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/ai-in-drug-discovery.asp

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.